China Approves Gc Pharmas Greengene F As A Therapy To Treat Haemophilia A

China Approves Gc Pharmas Greengene F As A Therapy To Treat Haemophilia A

By, Admin 13 August 2021

China National Medical Products Administration (Nmpa) Has Approved Gc Pharma'S Greengene F (Beroctocog Alfa) [Recombinant Human Coagulation Factor Viii For Injection] For The Control And Prophylaxis Of Bleeding Episodes In Individuals With Haemophilia A.The Collaboration Will Facilitate Gc China, A Leading Plasma-Derived Haemophilia Products Provider In China And Also A Gc Pharma&Rsquo;S Affiliate Company, Greengene F Will Be Available In China Within The First Half Of Next Year.Greengene F Was Initially Approved By The Korean Health Authority In 2010 For Control And Prevention Of Bleeding Episodes In Patients With Haemophilia A."The Approval Of Greengene F In China Marks An Important Milestone For Gc Pharma And Supports Our Ongoing Commitment To Treating Patients Living With Rare Disorder," Said Ec Huh, Ph.D., President Of Gc Pharma.In The Pivotal Phase Iii Clinical Trial Conducted In China, Which Served As The Foundation For The Approval, Greengene F Demonstrated Efficacy In Treating Hemophilia Patients. About 80 Percent Of Patients Showed Improvement In Symptoms Within 8 Hours After A Single Injection, Meeting Its Primary Efficacy Endpoints Of Hemostasis And Bleeding Prevention. The Trials Also Met Of Its Secondary Endpoints With 94 Percent Reduction Of Annual Bleeding And Annual Joint Bleeding Rates.The Trial Also Included Patient-Reported Quality Of Life (Qol) Metrics. Patients Treated With &Lsquo;Greengene F&Rsquo; Reported An Improvement In Hemophilia-Related Symptoms Compared To Before Receiving The Treatment.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!